Detalles de la búsqueda
1.
A Randomized Trial of Two Remote Health Care Delivery Models on the Uptake of Genetic Testing and Impact on Patient-Reported Psychological Outcomes in Families With Pancreatic Cancer: The Genetic Education, Risk Assessment, and Testing (GENERATE) Study.
Gastroenterology;
166(5): 872-885.e2, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38320723
2.
Regression models for average hazard.
Biometrics;
80(2)2024 Mar 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38771658
3.
Latinas in medicine: evaluating and understanding the experience of Latinas in medical education: a cross sectional survey.
BMC Med Educ;
24(1): 4, 2024 Jan 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38172800
4.
Ratio and difference of average hazard with survival weight: New measures to quantify survival benefit of new therapy.
Stat Med;
42(7): 936-952, 2023 03 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-36604833
5.
On assessing survival benefit of immunotherapy using long-term restricted mean survival time.
Stat Med;
42(8): 1139-1155, 2023 04 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36653933
6.
Clinical factors associated with skin neoplasms in individuals with Lynch syndrome in a longitudinal observational cohort.
J Am Acad Dermatol;
88(6): 1282-1290, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36773823
7.
Familial Burden and Other Clinical Factors Associated With Various Types of Cancer in Individuals With Lynch Syndrome.
Gastroenterology;
161(1): 143-150.e4, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33794268
8.
On permutation tests for comparing restricted mean survival time with small sample from randomized trials.
Stat Med;
39(20): 2655-2670, 2020 09 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32432805
9.
Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
Clin Trials;
17(6): 597-606, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32933339
10.
How Do the Accrual Pattern and Follow-Up Duration Affect the Hazard Ratio Estimate When the Proportional Hazards Assumption Is Violated?
Oncologist;
24(7): 867-871, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30201741
11.
A flexible and coherent test/estimation procedure based on restricted mean survival times for censored time-to-event data in randomized clinical trials.
Stat Med;
37(15): 2307-2320, 2018 07 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29682762
12.
Statistical Test/Estimation Methods Used in Contemporary Phase III Cancer Randomized Controlled Trials with Time-to-Event Outcomes.
Oncologist;
25(2): 91-93, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32043795
13.
Vascular injury markers associated with cognitive impairment in people with HIV on suppressive antiretroviral therapy.
AIDS;
37(14): 2137-2147, 2023 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37503603
14.
Vascular injury markers associated with cognitive impairment in people with HIV on suppressive antiretroviral therapy.
medRxiv;
2023 Jul 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-37546734
15.
Mentorship Experiences Are Not All the Same: A Survey Study of Oncology Trainees and Early-Career Faculty.
JCO Oncol Pract;
19(9): 808-818, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37192431
16.
PREMM5 distinguishes sporadic from Lynch syndrome-associated MMR-deficient/MSI-high colorectal cancer.
Fam Cancer;
22(4): 459-465, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37572151
17.
Development and Validation of the PREMMplus Model for Multigene Hereditary Cancer Risk Assessment.
J Clin Oncol;
40(35): 4083-4094, 2022 12 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35960913
18.
Comparison of Colorectal and Endometrial Microsatellite Instability Tumor Analysis and Premm5 Risk Assessment for Predicting Pathogenic Germline Variants on Multigene Panel Testing.
J Clin Oncol;
38(34): 4086-4094, 2020 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32997573
19.
Suggestions on Using Machine Learning Models and Cautions for Analyzing Censored Time-To-Event Outcomes.
JCO Precis Oncol;
8: e2400220, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38781547
20.
Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab as a Result of Adverse Events Lived Significantly Longer Than Patients Who Continued Treatment.
J Clin Oncol;
36(7): 720-721, 2018 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29337638